$PHBI the company progress, Peter Wojcik, President and CEO, stated, “We are very pleased to be working with Oscaleta, its team and its network of brokers/dealers as we move forward with our exciting business model.
PHBI negotiating a deal that is 85% of the closing bid price is a positive for our company and reflective of NASDAQ listed companies rates.”
#stocks #biotech
PHBI negotiating a deal that is 85% of the closing bid price is a positive for our company and reflective of NASDAQ listed companies rates.”
#stocks #biotech